Western Union Continues to Connect Communities and Economies at a Critical Time
25.6.2020 15:00:00 EEST | Business Wire | Press release
Western Union (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, today released its second annual Environmental, Social and Governance (ESG) Report, which spotlights the Company’s 2019 ESG progress. The report also highlights Western Union’s response and ongoing initiatives surrounding the COVID-19 pandemic and social justice movements across the globe in early 2020.
“Today, against the backdrop of COVID-19 and global protests against social injustice, business’s role in building a more united future has never seemed more relevant – or more urgent. Serving our stakeholders in today’s world takes determination and innovation. It demands that we build unity through ingenuity to create new, lasting solutions for people, businesses, and societies,” said Hikmet Ersek, President and CEO, Western Union. “This report provides an update on Western Union’s ESG efforts, and how we are addressing some of the most pressing global issues facing society, our shared environment, and our Company.”
The report highlights six key areas where Western Union is making an impact globally:
Connecting people and businesses to the global economy: Our services connect people and businesses pursuing global opportunities – for example, individuals looking to better the lives of their families, and businesses looking for new partners, customers, and markets. The transactions we process build bridges across economies, geographies, and cultures.
- In response to COVID-19, Western Union doubled down on its commitment to serve customers with a range of new offerings and resources including piloting home delivery of money transfers, introducing “digital location” concierge services to offer personalized phone or video support to help customers make digital money transfers, expanding westernunion.com to five additional countries bringing the total to more than 75, and expanding real-time account and wallet payout to 50 countries.
Fostering an engaging and inclusive workplace: Western Union works to build and support a workforce that reflects the global diversity of the 150 million customers we serve in more than 200 countries and territories around the world. It starts at the most senior levels of our business and manifests itself throughout our Board of Directors and our global workforce. We are actively engaging in open and honest dialogue with our employees and we are committed to playing a role in the fight for positive change globally. 2019 highlights include:
- Reaching gender parity with our customers and employees: approximately half of our customers and half of our global workforce are women.
- Our executive team in 2019 was comprised of 40% women and includes leaders born in 10 different countries who have wide-ranging global leadership experience.
Moving money with integrity: We are committed to using the right combination of people and technology to protect our customers and partners, keep illicit activity out of our network, and ensure we conduct our business with integrity.
- In 2019, we prevented $1.1 billion in fraudulent transactions. Overall industry data suggests a growing rate of fraudulent activity. Western Union’s fraud levels, however, are trending downward.
- Our Financial Intelligence Unit continues to partner with law enforcement and nonprofit entities to better target and disrupt human trafficking financial flows. This team has conducted approximately 1,800 human trafficking investigations since 2013, resulting in hundreds of arrests and the rescue of hundreds of victims.
Governing and managing for success: Western Union’s governance structures and practices provide oversight and guidance around critical issues, including ethics, board diversity, executive compensation, fair competition, data privacy, and cybersecurity, and board diversity. 2019 highlights include:
- Our Board is comprised of a wide range of nationalities from around the world.
- Three of our 11 Board members were women.
Safeguarding our shared environment: We are committed to acting responsibly to respect the environment and minimize our footprint.
- 25% of building materials, by value, are made of recycled materials at our global headquarters.
- We have equipped our major offices with state-of-the-art video conferencing technology, which reduced the need for air travel between locations, even prior to COVID-19.
Catalyzing change through the Western Union Foundation: The Western Union Foundation works to provide vulnerable youth with the skills needed to succeed in today’s global digital economy, and to support people across the globe through humanitarian relief.
- In 2019, the Western Union Foundation launched Opportunity Beyond Borders, a three-year and $15-million commitment to provide vulnerable youth with the skills and training needed to succeed in today’s global digital economy.
- As the impact of COVID-19 spread across the globe, Western Union and the Western Union Foundation announced a global matching challenge, with a total commitment of $1.3 million in customer, corporate, employee, and agent donations towards the global fight against the virus.
The Western Union 2019 ESG Report is available at: http://ir.westernunion.com/investor-relations/ESG/default.aspx. It is prepared in accordance with the Global Reporting Initiative (GRI) standards, and also includes responses to select relevant metrics from the Sustainability Accounting Standards Board (SASB) Standards.
WU-G
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of March 31, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005415/en/
Contact information
Western Union Contacts
Investor Relations:
Brendan Metrano; Brendan.metrano@wu.com
+1(720) 332-8089
Media Relations:
Western Union Global Communications
Rachel Rogala; Rachel.Rogala@wu.com
+ 1 (303) 808-2674
Pia De Lima; Pia.DeLima@wu.com
+1 (954) 260-5732
Western Union Americas
Margaret Fogarty; Margaret.Fogarty@wu.com
Western Union Middle East & Africa
Mohamed El Khalouki; Mohamed.ElKhalouki@wu.com
Western Union Asia-Pacific
Karen Santos; Karen.Santos2@wu.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
